---
title: Track early Parkinson disease progression
nct_id: NCT05767151
status: RECRUITING
sponsor: Xiangya Hospital of Central South University
study_type: OBSERVATIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT05767151"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT05767151"
last_fetched: "2026-05-10T14:07:40.545Z"
source: "Parkinson's Pathways (curated)"
---
# Track early Parkinson disease progression

**Goal (in five words):** Track early Parkinson disease progression

**Official Title:** The Chinese DENOVO Parkinson's Disease Registry

**Trial ID:** [NCT05767151](https://clinicaltrials.gov/study/NCT05767151)

## Key Facts

- **Status:** RECRUITING
- **Study Type:** OBSERVATIONAL
- **Sponsor:** Xiangya Hospital of Central South University
- **Target Enrollment:** 300 participants
- **Start Date:** 2021-01-01
- **Completion Date:** 2031-01-01
- **Conditions:** Parkinson Disease

## Summary For Families

The registry aims to map the early course of Parkinson's disease and find patterns or markers that could help with earlier diagnosis and better care down the road. It enrolls 300 people who are newly diagnosed and treatment naive, then collects standardized clinical assessments and follow-up data to see how symptoms and signs evolve over time. Eligible participants are 30 to 75 years old, diagnosed by MDS criteria with disease duration of two years or less, Hoehn-Yahr stage 2 or lower, not yet on antiparkinsonian drugs, and without cognitive impairment or other parkinsonism syndromes.

## Eligibility

- **Minimum age:** 30 Years
- **Maximum age:** 75 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

1. Participants were diagnosed by MDS Clinical Diagnostic Criteria for PD
2. Disease duration ≤ 2 years at baseline
3. Hoehn-Yahr stage ≤2 at baseline
4. The age of PD patients ranges from 30 to 75 years old
5. Participants were naive to antiparkinsonian therapy
6. Able to Written informed consent

Exclusion Criteria:

1. Participants were diagnosed with parkinsonism-syndrome
2. Participants were treated with antiparkinsonian drugs at baseline
3. Participants with cognitive impairment
4. Unable to Written informed consent
```

## Locations (1)

- Xiangya Hospital of Central South University, Changsha, Hunan, China _(28.1987, 112.9709)_
  - Jifeng Guo, Ph.D — (CONTACT) — +8613974936815 — guojifeng2003@163.com
  - Beisha Tang, MD — (CONTACT) — +8613974856709 — bstang7398@163.com

## Central Contacts

- Jifeng Guo, Ph.D — (CONTACT) — +8613974936815 — guojifeng2003@163.com
- Beisha Tang, MD — (CONTACT) — +8613974856709 — bstang7398@163.com

---

*Canonical: https://parkinsonspathways.com/trial/NCT05767151*  
*HTML version: https://parkinsonspathways.com/trial/NCT05767151*  
*Source data: https://clinicaltrials.gov/study/NCT05767151*